Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
08:00am, Thursday, 25'th Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
08:00am, Tuesday, 23'rd Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) (the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardi
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 12'th Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro
Scholar Rock: Solid Data And Good Prospects
05:32am, Friday, 12'th Jan 2024
Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myo
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
01:57pm, Tuesday, 02'nd Jan 2024
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes yo
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 19'th Dec 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 15'th Dec 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 17'th Nov 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro
Scholar Rock Holding Corporation (SRRK) Q3 2023 Earnings Call Transcript
02:18pm, Tuesday, 07'th Nov 2023
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Rushmie Nofsinger - Vice President, Investor Relations & Corporate Aff
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
07:15am, Tuesday, 07'th Nov 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
11:17am, Monday, 06'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
10:33am, Tuesday, 31'st Oct 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed th
Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look
05:44pm, Wednesday, 25'th Oct 2023
The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. D
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
01:32pm, Tuesday, 24'th Oct 2023
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the
